Guy Van Meter is the Chief Business Officer of Adimab, LLC and has been with the company since 2008. Adimab, a leading antibody engineering company, has developed from a start-up company into a $5B+ private company with over 140 partnerships and more than 650 therapeutic programs, including 6 marketed programs. Mr. Van Meter is also a board member of Adimab Royalty Co. (ARC), which controls the royalty rights for Adimab’s therapeutic programs and seeks to monetize royalty assets or distribute royalty revenue to shareholders.
Before joining Adimab, Mr. Van Meter was part of Pfizer’s Business Development team for their RNAi and Regenerative Medicine divisions. Prior to Pfizer, he managed the antibody technology business for Dyax Corp, generating more than 50 partnerships. He also worked in product development at Alkermes, worked as a Research Associate at both Harvard and Yale, and earned his MBA from Babson’s FW Olin Graduate School of Business.